Literature DB >> 11934820

Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats.

Akira Nagakura1, Makiko Niimura, Satoshi Takeo.   

Abstract

The effects of treatment with rolipram, a specific phosphodiesterase IV inhibitor, on learning and memory function and on the cyclic AMP/PKA/CREB signal transduction system were examined in rats with microsphere embolism (ME)-induced cerebral ischaemia. Sustained cerebral ischaemia was induced by the injection of 900 microspheres (48 microm in diameter) into the right hemisphere of the rat brain. The animals were treated once daily with 3 mg kg(-1) rolipram i.p. from 6 h after the onset of the operation for consecutive 10 days. Microsphere-embolized rats showed prolongation of the escape latency in the water maze task starting from day 7 after the operation and lasting for 3 consecutive days. Treatment with rolipram reduced the escape latency. ME decreased the cyclic AMP content, cytosolic PKA Cbeta level, and nuclear PKA Calpha and Cbeta levels, as well as reduced the pCREB level and the DNA-binding activity of CREB in the cerebral cortex and hippocampus on day 10 after the operation. These alterations were attenuated by treatment with rolipram. These results suggest that ME-induced failure in learning and memory function may be mediated by dysfunction of the cyclic AMP/PKA/CREB signal transduction system, that rolipram may ameliorate ME-induced impairment of learning and memory function, and that the drug effect may be partly attributed to activation of the cyclic AMP/PKA/CREB signal transduction system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934820      PMCID: PMC1573294          DOI: 10.1038/sj.bjp.0704629

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  45 in total

1.  The differential response of protein kinase A to cyclic AMP in discrete brain areas correlates with the abundance of regulatory subunit II.

Authors:  C Ventra; A Porcellini; A Feliciello; A Gallo; M Paolillo; E Mele; V E Avvedimento; G Schettini
Journal:  J Neurochem       Date:  1996-04       Impact factor: 5.372

2.  Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor.

Authors:  M Asanuma; S Nishibayashi; E Iwata; Y Kondo; T Nakanishi; M G Vargas; N Ogawa
Journal:  Brain Res Mol Brain Res       Date:  1996-09-05

3.  Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type.

Authors:  M Yamamoto-Sasaki; H Ozawa; T Saito; M Rösler; P Riederer
Journal:  Brain Res       Date:  1999-04-10       Impact factor: 3.252

4.  Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats.

Authors:  F Block; A Tondar; W Schmidt; M Schwarz
Journal:  Neuroreport       Date:  1997-12-01       Impact factor: 1.837

5.  CREB1 encodes a nuclear activator, a repressor, and a cytoplasmic modulator that form a regulatory unit critical for long-term facilitation.

Authors:  D Bartsch; A Casadio; K A Karl; P Serodio; E R Kandel
Journal:  Cell       Date:  1998-10-16       Impact factor: 41.582

Review 6.  On the role of the hippocampus in learning and memory in the rat.

Authors:  L E Jarrard
Journal:  Behav Neural Biol       Date:  1993-07

7.  Serotonin induces temporally and mechanistically distinct phases of persistent PKA activity in Aplysia sensory neurons.

Authors:  U Müller; T J Carew
Journal:  Neuron       Date:  1998-12       Impact factor: 17.173

8.  Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil.

Authors:  H Kato; T Araki; Y Itoyama; K Kogure
Journal:  Eur J Pharmacol       Date:  1995-01-05       Impact factor: 4.432

9.  Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein.

Authors:  R Bourtchuladze; B Frenguelli; J Blendy; D Cioffi; G Schutz; A J Silva
Journal:  Cell       Date:  1994-10-07       Impact factor: 41.582

10.  Inhibitors of cAMP-dependent protein kinase impair long-term memory formation in day-old chicks.

Authors:  W Q Zhao; G M Polya; B H Wang; M E Gibbs; G L Sedman; K T Ng
Journal:  Neurobiol Learn Mem       Date:  1995-09       Impact factor: 2.877

View more
  25 in total

Review 1.  Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.

Authors:  David J Titus; Anthony A Oliva; Nicole M Wilson; Coleen M Atkins
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Structural and functional modifications in glutamateric synapses following prolonged ethanol exposure.

Authors:  L Judson Chandler; Ezekiel Carpenter-Hyland; Adam W Hendricson; Regina E Maldve; Richard A Morrisett; Feng C Zhou; Youssef Sari; Richard Bell; Karen K Szumlinski
Journal:  Alcohol Clin Exp Res       Date:  2006-02       Impact factor: 3.455

3.  Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.

Authors:  Ying Xiong; Hai-Ting Lu; Yongjian Li; Guang-Fu Yang; Chang-Guo Zhan
Journal:  Biophys J       Date:  2006-09-01       Impact factor: 4.033

4.  Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury.

Authors:  C M Atkins; Y Kang; C Furones; J S Truettner; O F Alonso; W D Dietrich
Journal:  J Neurosci Res       Date:  2012-04-26       Impact factor: 4.164

5.  The phosphodiesterase 5 inhibitor, KJH-1002, reverses a mouse model of amnesia by activating a cGMP/cAMP response element binding protein pathway and decreasing oxidative damage.

Authors:  Lijun Zhang; Jae Hong Seo; Huan Li; Ghilsoo Nam; Hyun Ok Yang
Journal:  Br J Pharmacol       Date:  2018-07-10       Impact factor: 8.739

6.  Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.

Authors:  Bing Gong; Ottavio V Vitolo; Fabrizio Trinchese; Shumin Liu; Michael Shelanski; Ottavio Arancio
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 7.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Cilostazol improves hippocampus-dependent long-term memory in mice.

Authors:  Shuichi Yanai; Yuki Semba; Hideki Ito; Shogo Endo
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 9.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

10.  Impaired cognition and attention in adults: pharmacological management strategies.

Authors:  Hervé Allain; Yvette Akwa; Lucette Lacomblez; Alain Lieury; Danièle Bentué-Ferrer
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.